Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 276


[Physiopathology and genetics of epilepsy: recent data].

Stutzmann JM, Scatton B.

Biol Aujourdhui. 2011;205(1):29-31. doi: 10.1051/jbio/2011003. Epub 2011 Apr 19. French.


[The discovery process in the pharmaceutical industry].

Scatton B.

J Soc Biol. 2009;203(3):249-69. doi: 10.1051/jbio:2009030. Epub 2009 Oct 16. Review. French.


Effects of the beta3-adrenoceptor (Adrb3) agonist SR58611A (amibegron) on serotonergic and noradrenergic transmission in the rodent: relevance to its antidepressant/anxiolytic-like profile.

Claustre Y, Leonetti M, Santucci V, Bougault I, Desvignes C, Rouquier L, Aubin N, Keane P, Busch S, Chen Y, Palejwala V, Tocci M, Yamdagni P, Didier M, Avenet P, Le Fur G, Oury-Donat F, Scatton B, Steinberg R.

Neuroscience. 2008 Oct 2;156(2):353-64. doi: 10.1016/j.neuroscience.2008.07.011. Epub 2008 Jul 11.


Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia.

Boulay D, Pichat P, Dargazanli G, Estenne-Bouhtou G, Terranova JP, Rogacki N, Stemmelin J, Coste A, Lanneau C, Desvignes C, Cohen C, Alonso R, Vigé X, Biton B, Steinberg R, Sevrin M, Oury-Donat F, George P, Bergis O, Griebel G, Avenet P, Scatton B.

Pharmacol Biochem Behav. 2008 Nov;91(1):47-58. doi: 10.1016/j.pbb.2008.06.009. Epub 2008 Jun 24.


Peripheral type benzodiazepine binding sites as a tool for the detection and quantification of CNS injury.

Benavides J, Dubois A, Scatton B.

Curr Protoc Neurosci. 2001 May;Chapter 7:Unit7.16. doi: 10.1002/0471142301.ns0716s09.


CB1 receptor-mediated control of the release of endocannabinoids (as assessed by microdialysis coupled with LC/MS) in the rat hypothalamus.

Béquet F, Uzabiaga F, Desbazeille M, Ludwiczak P, Maftouh M, Picard C, Scatton B, Le Fur G.

Eur J Neurosci. 2007 Dec;26(12):3458-64. Epub 2007 Dec 4.


New perspectives for the treatment of disorders of sleep and arousal.

Sanger DJ, Soubrane C, Scatton B.

Ann Pharm Fr. 2007 Jul;65(4):268-74. Review.


Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats.

Gary-Bobo M, Elachouri G, Gallas JF, Janiak P, Marini P, Ravinet-Trillou C, Chabbert M, Cruccioli N, Pfersdorff C, Roque C, Arnone M, Croci T, Soubrié P, Oury-Donat F, Maffrand JP, Scatton B, Lacheretz F, Le Fur G, Herbert JM, Bensaid M.

Hepatology. 2007 Jul;46(1):122-9.


Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders.

Stemmelin J, Cohen C, Terranova JP, Lopez-Grancha M, Pichat P, Bergis O, Decobert M, Santucci V, Françon D, Alonso R, Stahl SM, Keane P, Avenet P, Scatton B, le Fur G, Griebel G.

Neuropsychopharmacology. 2008 Feb;33(3):574-87. Epub 2007 Apr 25.


SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile.

Biton B, Bergis OE, Galli F, Nedelec A, Lochead AW, Jegham S, Godet D, Lanneau C, Santamaria R, Chesney F, Léonardon J, Granger P, Debono MW, Bohme GA, Sgard F, Besnard F, Graham D, Coste A, Oblin A, Curet O, Vigé X, Voltz C, Rouquier L, Souilhac J, Santucci V, Gueudet C, Françon D, Steinberg R, Griebel G, Oury-Donat F, George P, Avenet P, Scatton B.

Neuropsychopharmacology. 2007 Jan;32(1):1-16. Epub 2006 Oct 4.


SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia.

Pichat P, Bergis OE, Terranova JP, Urani A, Duarte C, Santucci V, Gueudet C, Voltz C, Steinberg R, Stemmelin J, Oury-Donat F, Avenet P, Griebel G, Scatton B.

Neuropsychopharmacology. 2007 Jan;32(1):17-34. Epub 2006 Aug 23.


The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes.

Gary-Bobo M, Elachouri G, Scatton B, Le Fur G, Oury-Donat F, Bensaid M.

Mol Pharmacol. 2006 Feb;69(2):471-8. Epub 2005 Nov 9.


Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic.

Depoortère R, Dargazanli G, Estenne-Bouhtou G, Coste A, Lanneau C, Desvignes C, Poncelet M, Heaulme M, Santucci V, Decobert M, Cudennec A, Voltz C, Boulay D, Terranova JP, Stemmelin J, Roger P, Marabout B, Sevrin M, Vigé X, Biton B, Steinberg R, Françon D, Alonso R, Avenet P, Oury-Donat F, Perrault G, Griebel G, George P, Soubrié P, Scatton B.

Neuropsychopharmacology. 2005 Nov;30(11):1963-85.


SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist, alleviates disturbances of novelty discrimination in a social context in rats, a putative model of selective attention deficit.

Terranova JP, Chabot C, Barnouin MC, Perrault G, Depoortere R, Griebel G, Scatton B.

Psychopharmacology (Berl). 2005 Aug;181(1):134-44. Epub 2005 Apr 14.


Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents.

Griebel G, Stemmelin J, Scatton B.

Biol Psychiatry. 2005 Feb 1;57(3):261-7.


SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.

Aubin N, Barneoud P, Carter C, Caille D, Sontag N, Marc C, Lolivier J, Gardes A, Perron C, Le Kim A, Charieras T, Pandini M, Burnier P, Puech F, Jegham S, George P, Scatton B, Curet O.

J Pharmacol Exp Ther. 2004 Sep;310(3):1171-82. Epub 2004 Jun 3.


SSR126768A (4-chloro-3-[(3R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)-benzamide, hydrochloride): a new selective and orally active oxytocin receptor antagonist for the prevention of preterm labor.

Serradeil-Le Gal C, Valette G, Foulon L, Germain G, Advenier C, Naline E, Bardou M, Martinolle JP, Pouzet B, Raufaste D, Garcia C, Double-Cazanave E, Pauly M, Pascal M, Barbier A, Scatton B, Maffrand JP, Le Fur G.

J Pharmacol Exp Ther. 2004 Apr;309(1):414-24. Epub 2004 Jan 13.


SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist. I: Neurochemical and electrophysiological profile.

Claustre Y, Peretti DD, Brun P, Gueudet C, Allouard N, Alonso R, Lourdelet J, Oblin A, Damoiseau G, Françon D, Suaud-Chagny MF, Steinberg R, Sevrin M, Schoemaker H, George P, Soubrié P, Scatton B.

Neuropsychopharmacology. 2003 Dec;28(12):2064-76.


SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity.

Depoortere R, Boulay D, Perrault G, Bergis O, Decobert M, Françon D, Jung M, Simiand J, Soubrié P, Scatton B.

Neuropsychopharmacology. 2003 Nov;28(11):1889-902.


SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation.

Cohen C, Bergis OE, Galli F, Lochead AW, Jegham S, Biton B, Leonardon J, Avenet P, Sgard F, Besnard F, Graham D, Coste A, Oblin A, Curet O, Voltz C, Gardes A, Caille D, Perrault G, George P, Soubrie P, Scatton B.

J Pharmacol Exp Ther. 2003 Jul;306(1):407-20. Epub 2003 Apr 7.


SL651498, a GABAA receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasms.

Griebel G, Perrault G, Simiand J, Cohen C, Granger P, Depoortere H, Françon D, Avenet P, Schoemaker H, Evanno Y, Sevrin M, George P, Scatton B.

CNS Drug Rev. 2003 Spring;9(1):3-20. Review.


SL65.0155, a novel 5-hydroxytryptamine(4) receptor partial agonist with potent cognition-enhancing properties.

Moser PC, Bergis OE, Jegham S, Lochead A, Duconseille E, Terranova JP, Caille D, Berque-Bestel I, Lezoualc'h F, Fischmeister R, Dumuis A, Bockaert J, George P, Soubrié P, Scatton B.

J Pharmacol Exp Ther. 2002 Aug;302(2):731-41.


SSR180575 (7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide), a peripheral benzodiazepine receptor ligand, promotes neuronal survival and repair.

Ferzaz B, Brault E, Bourliaud G, Robert JP, Poughon G, Claustre Y, Marguet F, Liere P, Schumacher M, Nowicki JP, Fournier J, Marabout B, Sevrin M, George P, Soubrie P, Benavides J, Scatton B.

J Pharmacol Exp Ther. 2002 Jun;301(3):1067-78.


Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.

Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B, Maffrand JP, Soubrie P.

Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6370-5. Epub 2002 Apr 16.


4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A): a potent and selective corticotrophin-releasing factor(1) receptor antagonist. I. Biochemical and pharmacological characterization.

Gully D, Geslin M, Serva L, Fontaine E, Roger P, Lair C, Darre V, Marcy C, Rouby PE, Simiand J, Guitard J, Gout G, Steinberg R, Rodier D, Griebel G, Soubrie P, Pascal M, Pruss R, Scatton B, Maffrand JP, Le Fur G.

J Pharmacol Exp Ther. 2002 Apr;301(1):322-32.


Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist.

Serradeil-Le Gal C, Wagnon J, Simiand J, Griebel G, Lacour C, Guillon G, Barberis C, Brossard G, Soubrié P, Nisato D, Pascal M, Pruss R, Scatton B, Maffrand JP, Le Fur G.

J Pharmacol Exp Ther. 2002 Mar;300(3):1122-30.


The preclinical pharmacologic profile of tiapride.

Scatton B, Cohen C, Perrault G, Oblin A, Claustre Y, Schoemaker H, Sanger DJ, Rouquier L, Porsolt R.

Eur Psychiatry. 2001 Jan;16 Suppl 1:29s-34s.


SL651498: an anxioselective compound with functional selectivity for alpha2- and alpha3-containing gamma-aminobutyric acid(A) (GABA(A)) receptors.

Griebel G, Perrault G, Simiand J, Cohen C, Granger P, Decobert M, Françon D, Avenet P, Depoortere H, Tan S, Oblin A, Schoemaker H, Evanno Y, Sevrin M, George P, Scatton B.

J Pharmacol Exp Ther. 2001 Aug;298(2):753-68.


Pharmacological and molecular targets in the search for novel antipsychotics.

Scatton B, Sanger DJ.

Behav Pharmacol. 2000 Jun;11(3-4):243-56. Review.


Subunit composition of rat ventral spinal cord GABA(A) receptors, assessed by single cell RT-multiplex PCR.

Ruano D, Létang V, Biton B, Avenet P, Benavides J, Scatton B, Vitorica J.

Neuroreport. 2000 Sep 28;11(14):3169-73.


Preclinical profile of befloxatone, a new reversible MAO-A inhibitor.

Curet O, Damoiseau-Ovens G, Sauvage C, Sontag N, Avenet P, Depoortere H, Caille D, Bergis O, Scatton B.

J Affect Disord. 1998 Dec;51(3):287-303. Review.


Neuroprotective effects of eliprodil in retinal excitotoxicity and ischemia.

Kapin MA, Doshi R, Scatton B, DeSantis LM, Chandler ML.

Invest Ophthalmol Vis Sci. 1999 May;40(6):1177-82.


Neuroprotection afforded by a combination of eliprodil and a thrombolytic agent, rt-PA, in a rat thromboembolic stroke model.

Lekieffre D, Benavides J, Scatton B, Nowicki JP.

Brain Res. 1997 Nov 21;776(1-2):88-95.


Neuroprotective effects of eliprodil in a rat hippocampal slice hypoxia model.

Santamaria R, Françon D, Depoortere H, Scatton B.

Ann N Y Acad Sci. 1997 Oct 15;825:232-8. No abstract available.


Quantitative motor assessment in FALS mice: a longitudinal study.

Barnéoud P, Lolivier J, Sanger DJ, Scatton B, Moser P.

Neuroreport. 1997 Sep 8;8(13):2861-5.


Amisulpride: from animal pharmacology to therapeutic action.

Scatton B, Claustre Y, Cudennec A, Oblin A, Perrault G, Sanger DJ, Schoemaker H.

Int Clin Psychopharmacol. 1997 May;12 Suppl 2:S29-36. Review.


Antagonist properties of eliprodil and other NMDA receptor antagonists at rat NR1A/NR2A and NR1A/NR2B receptors expressed in Xenopus oocytes.

Avenet P, Léonardon J, Besnard F, Graham D, Depoortere H, Scatton B.

Neurosci Lett. 1997 Feb 21;223(2):133-6.


Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.

Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, Oblin A, Gonon F, Carter C, Benavides J, Scatton B.

J Pharmacol Exp Ther. 1997 Jan;280(1):83-97.


Protracted treatment with diazepam reduces benzodiazepine1 receptor-mediated potentiation of gamma-aminobutyric acid-induced currents in dissociated rat hippocampal neurons.

Itier V, Granger P, Perrault G, Depoortere H, Scatton B, Avenet P.

J Pharmacol Exp Ther. 1996 Dec;279(3):1092-9.


[The place of amisulpride in the atypical neuroleptic class].

Perrault G, Schoemaker H, Scatton B.

Encephale. 1996 Jun;22 Spec No 2:3-8. Review. French.


Zolpidem functionally discriminates subtypes of native GABAA receptors in acutely dissociated rat striatal and cerebellar neurons.

Itier V, Depoortere H, Scatton B, Avenet P.

Neuropharmacology. 1996 Feb;35(2):137-45.


Antagonist properties of the stereoisomers of ifenprodil at NR1A/NR2A and NR1A/NR2B subtypes of the NMDA receptor expressed in Xenopus oocytes.

Avenet P, Léonardon J, Besnard F, Graham D, Frost J, Depoortere H, Langer SZ, Scatton B.

Eur J Pharmacol. 1996 Jan 25;296(2):209-13.


Central benzodiazepine receptor occupancy by zolpidem in the human brain as assessed by positron emission tomography.

Abadie P, Rioux P, Scatton B, Zarifian E, Barré L, Patat A, Baron JC.

Eur J Pharmacol. 1996 Jan 4;295(1):35-44.


Ischemic stroke: treatment on the horizon.

Giroux C, Scatton B.

Eur Neurol. 1996;36(2):61-4. Review. No abstract available.


Block of P-type Ca2+ channels by the NMDA receptor antagonist eliprodil in acutely dissociated rat Purkinje cells.

Biton B, Granger P, Depoortere H, Scatton B, Avenet P.

Eur J Pharmacol. 1995 Dec 27;294(1):91-100.


Modulation of the gamma-aminobutyric acid type A receptor by the antiepileptic drugs carbamazepine and phenytoin.

Granger P, Biton B, Faure C, Vige X, Depoortere H, Graham D, Langer SZ, Scatton B, Avenet P.

Mol Pharmacol. 1995 Jun;47(6):1189-96.


In vivo and in vitro interaction of the novel selective histamine H1 receptor antagonist mizolastine with H1 receptors in the rodent.

Benavides J, Schoemaker H, Dana C, Claustre Y, Delahaye M, Prouteau M, Manoury P, Allen J, Scatton B, Langer SZ, et al.

Arzneimittelforschung. 1995 May;45(5):551-8.


Supplemental Content

Loading ...
Support Center